Scinai Immunotherapeutics Ltd (SCNI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Scinai Immunotherapeutics Ltd stock (SCNI) is currently trading at $0.67. Scinai Immunotherapeutics Ltd PE ratio is 0.17. Scinai Immunotherapeutics Ltd PS ratio (Price-to-Sales) is 1.89. Analyst consensus price target for SCNI is $700.00. WallStSmart rates SCNI as Hold.
- SCNI PE ratio analysis and historical PE chart
- SCNI PS ratio (Price-to-Sales) history and trend
- SCNI intrinsic value — DCF, Graham Number, EPV models
- SCNI stock price prediction 2025 2026 2027 2028 2029 2030
- SCNI fair value vs current price
- SCNI insider transactions and insider buying
- Is SCNI undervalued or overvalued?
- Scinai Immunotherapeutics Ltd financial analysis — revenue, earnings, cash flow
- SCNI Piotroski F-Score and Altman Z-Score
- SCNI analyst price target and Smart Rating
Scinai Immunotherapeutics
📊 No data available
Try selecting a different time range
SCNI Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Scinai Immunotherapeutics Ltd (SCNI)
SCNI trades at a significant discount to its Graham intrinsic value of $187.20, offering a 100% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Scinai Immunotherapeutics Ltd (SCNI) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, revenue growth. Concerns around market cap and operating margin. Fundamentals are solid but monitor weak areas for improvement.
Scinai Immunotherapeutics Ltd (SCNI) Key Strengths (6)
Revenue surging 36.10% year-over-year
Earnings per share surging 87.20% year-over-year
Keeps $448 of every $100 in revenue as net profit
Paying $1.89 for every $1 of annual revenue
Trading at 1.10x book value, attractively priced
Solid profitability: $18 profit per $100 equity
Supporting Valuation Data
Scinai Immunotherapeutics Ltd (SCNI) Areas to Watch (3)
Losing money on operations
Very low institutional interest at 5.23%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Scinai Immunotherapeutics Ltd (SCNI) Detailed Analysis Report
Overall Assessment
This company scores 61/100 in our Smart Analysis, earning a C+ grade. Out of 9 metrics analyzed, 6 register as strengths (avg 8.8/10) while 3 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, EPS Growth, Profit Margin. Valuation metrics including Price/Sales (1.89), Price/Book (1.10) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 17.90%, Profit Margin at 448.40%. Growth metrics are encouraging with Revenue Growth at 36.10%, EPS Growth at 87.20%.
The Bear Case
The primary concerns are Operating Margin, Institutional Own., Market Cap. Profitability pressure is visible in Operating Margin at -486.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 17.90% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 36.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Revenue Growth, EPS Growth) and negatives (Operating Margin, Institutional Own.). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SCNI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SCNI's Price-to-Sales ratio of 1.89x sits near its historical average of 2.15x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 26% below its historical high of 2.56x set in Mar 2026, and 0% above its historical low of 1.89x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~2.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Scinai Immunotherapeutics Ltd (SCNI) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Scinai Immunotherapeutics Ltd is a strong growth company balancing expansion with improving profitability. Revenue reached 1M with 36% growth year-over-year. Profit margins are strong at 448.4%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 36% YoY, reaching 1M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 49% of revenue (564,628) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -1M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Scinai Immunotherapeutics Ltd maintain 36%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.90, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Scinai Immunotherapeutics Ltd.
Bottom Line
Scinai Immunotherapeutics Ltd offers an attractive blend of growth (36% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Scinai Immunotherapeutics Ltd(SCNI)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Scinai Immunotherapeutics Ltd is an innovative biotechnology firm at the forefront of developing advanced immunotherapy solutions, particularly targeting cancer and autoimmune disorders. Leveraging its proprietary immune modulation platform, Scinai is advancing a promising clinical pipeline designed to deliver transformative therapies that enhance patient outcomes. Guided by a seasoned leadership team with extensive expertise in immunology and drug development, the company is poised to capitalize on the burgeoning demand for groundbreaking immunotherapeutics in the global healthcare market. Scinai's commitment to rigorous research and strategic partnerships further positions it for significant growth and impact within the biopharmaceutical industry.